I schemic stroke is caused by a blockage of blood flow to the brain. A leading cause of death and disability globally, each year more than 15 million people are estimated to suffer a stroke, including more than two million people in the United States, Japan, and European Union combined. According to the American Heart Association, ischemic strokes comprise more than 85% of all strokes. Current standard of care for ischemic stroke involves the administration of a thrombolytic agent such as tissue plasminogen activator (tPA) within 3 to 4 hours after a stroke has occurred, a narrow window that results in only a small percentage of patients receiving such treatment.
In light of this significant unmet clinical need, Athersys has developed a cell therapeutic, MultiStem, as a platform for treating acute central nervous system injury including stroke, traumatic brain injury, and spinal cord injury. [1] [2] [3] [4] [5] [6] The therapeutic premise reflects the strong immunomodulatory and anti-inflammatory influence shown by adherent (mesenchymal stromal cell-like) stem cells and posits that administration of MultiStem early after injury can diminish the systemic inflammatory response contributing to significant pathology and comorbidity in stroke. This hypothesis is supported by preclinical data demonstrating the role of splenic lymphocytes in onset of stroke pathology. When this population is absent or modulated, a striking prevention of injury and recovery benefit is seen. [7] [8] [9] Accordingly, an exploratory Phase II clinical study was designed to test the core hypotheses and to determine patient stratification and dose regimens for subsequent development.
MULTISTEM
MultiStem is a cell therapeutic isolated from adult marrow and expanded ex vivo for clinical use. Cells in this class have shown utility when used allogeneically and without patient matching, based on expression of metabolic and biologic factors which modulate the adaptive immune system away from immune sensitization. 10 MultiStem has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors produced in response to signals of inflammation and tissue damage. MultiStem therapy's potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. The product represents a unique "off-the-shelf" stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression.
PHASE II CLINICAL STUDY DESIGN
The randomized, double-blind, placebo-controlled Phase II clinical trial was conducted at 33 sites in the United States and the United Kingdom. 11 The study was conducted in two parts-a small dose selection phase involving 16 patients in two cohorts, followed by a larger efficacy phase of 118 patients. The evaluable patient population included eight patients from Cohort 2 and the Cohort 3 patients, who all received a high dose of MultiStem cells or placebo.
The study enrolled subjects who received either Mul-tiStem treatment or placebo 1 to 2 days after the stroke. The primary endpoints for the study include safety over the first 7 days after treatment and global stroke recovery at Day 90, which assesses disability (modified Rankin score 2), neurologic deficit (NIH Stroke Scale [NIHSS], D 75%), and activities of daily living (Barthel index [BI] 95%). Additionally, there are secondary and exploratory endpoints evaluating elements of recovery and dysfunction, including biomarkers associated with subject condition and recovery and safety variables over the study period. Of the patients evaluated in the study, 65 patients were in the MultiStem treatment group and 61 patients were in the placebo group. Among the enrolled patients, the groups were generally evenly balanced in terms of baseline stroke characteristics (Table 1) .
Interim results from this exploratory Phase II clinical study of the intravenous (IV) administration of MultiStem cell therapy to treat patients who have suffered an ischemic stroke demonstrate favorable safety and tolerability for MultiStem, consistent with prior studies. With respect to a composite scoring for primary and secondary endpoints, the cell therapy did not show a difference at 90 days compared to placebo. However, MultiStem treatment was associated with lower rates of mortality and life-threatening adverse events, infections, and pulmonary events. Furthermore, post hoc analysis shows that patients who received MultiStem treatment earlier in the treatment window had more robust recovery rates in comparison to placebo and relative to patients who received later MultiStem treatment.
The interim analysis results are listed in detail below:
MultiStem cell therapy demonstrated favorable tolerability and safety profile through the evaluation date, which was at least 90 days for all patients. Patients who received IV administration of Multi-Stem did not show a significant difference from placebo-treated patients for the primary endpoint (Global Stroke Recovery Assessment) and the related secondary endpoints-which were defined as the proportion of patients achieving a modified Rankin scale (mRS) value of 0 to 2, improvement in the NIHSS by at least 75% and achieving BI of at least 95 on Day 90. Among all subjects who received MultiStem treatment, 15.4% of patients achieved an excellent outcome, defined clinically as attaining mRS of 0 to 1, NIHSS of 0 to 1, and BI of at least 95, compared to 6.6% of patients who received placebo (p 5 0.10). As described in Table 2 , patients who received Mul-tiStem treatment earlier in the treatment window (24-36 hr poststroke) exhibited more favorable recovery on the primary and key secondary endpoints than patients who received placebo or patients who received MultiStem treatment later (e.g., excellent outcome; p 5 0.03), and this treatment effect was even more pronounced the earlier the MultiStem administration within the 24-to 36-hr time frame. A higher proportion of patients who received treatment with MultiStem achieved a good clinical outcome by Day 7 after treatment, defined as achieving mRS of 0 to 2, which was 12.9% for patients receiving MultiStem, compared to 5.2% of patients who received placebo, and a similar pattern was seen for improvement in NIHSS of at least 75%, which was achieved by 10.2% of MultiStem treated patients versus 3.9% of patients who were treated with placebo. Mortality was lower among patients who received treatment with MultiStem in comparison with placebo. There were nine subject deaths (14.8%) among those receiving treatment with placebo and only four patient deaths (6.2%) among patients receiving treatment with MultiStem. The MultiStem treatment group had a lower rate of life-threatening adverse events and death (p 5 0.04) and also exhibited lower rates of pulmonary events (p 5 0.08) and infections. The MultiStem-treated group also had a significantly lower level of circulating CD31 T cells at 2 days after dosing (p < 0.01), suggesting a reduction in the inflammatory response after stroke, consistent with the therapeutic hypothesis.
As noted above, post hoc analyses show that earlier Multi-Stem administration appears to provide substantial benefit, as evident in Table 2 .
This exploratory trial represents the first cell based Phase II clinical study for stroke and was designed to evaluate the safety and efficacy of a single dose of MultiStem 24 to 48 hours after the occurrence of the stroke. This treatment window extends well beyond the limits of current standard of care, treatment with tPA, which may only be administered within the first several hours after a stroke. The core hypothesis for mode of action was validated, with the finding that induction of circulating T cells by stroke was dramatically and statistically reduced after MultiStem administration. This correlated with the significant reduction in death and infectious complications and validates this core understanding. Interim analysis of core inflammatory biomarkers, notably IL-6, show their down regulation correlating with MultiStem treatment.
While the trial did not achieve the primary or component secondary endpoints, the evidence indicating that patients who received MultiStem treatment early appeared to exhibit meaningfully better clinical outcomes and recovery is promising. The results appear to confirm that the window of intervention with MultiStem therapy may extend beyond the limits of current care using tPA.
